Page last updated: 2024-08-24

ibandronic acid and Bone Fractures

ibandronic acid has been researched along with Bone Fractures in 62 studies

Research

Studies (62)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	34 (54.84)	29.6817
2010's	26 (41.94)	24.3611
2020's	2 (3.23)	2.80

Authors

Authors	Studies
Bartsch, R; Borchert, J; Hadji, P; Kossack, N; O'Kelly, J; Pignot, M	1
McConnell, M; Shieh, A	1
Boyanov, M; Intorcia, M; Petkova, R; Petranova, T; Psachoulia, E; Shinkov, A	1
Yalla, N	1
Hagino, H; Hashimoto, J; Ito, M; Mizunuma, H; Nakamura, T; Nakano, T; Tobinai, M	1
Cerdá, D; Gifre, L; Guañabens, N; Monegal, A; Muxí, Á; Parés, A; Peris, P	1
Adamidou, F; Anagnostis, P; Charizopoulou, M; Garipidou, V; Goulis, DG; Karagiannis, A; Karras, S; Vakalopoulou, S; Vyzantiadis, TA	1
Benhamou, CL; Binkley, N; Bolognese, MA; Bone, HG; Bonnick, SL; Czerwinski, E; Ferreira, I; Ghelani, P; Hall, JW; Moffett, A; Palacios, S; Recknor, C; Siddhanti, S; Wagman, RB	1
Gamsjaeger, S; Klaushofer, K; Misof, BM; Muschitz, C; Paschalis, EP; Patsch, JM; Pietschmann, P; Prokop, E; Resch, H; Roschger, P	1
Hagino, H; Hashimoto, J; Matsunaga, M; Nakamura, T; Tobinai, M; Yoshida, S	1
Joa, KL; Jung, HY; Kim, CH; Kim, HS; Kim, MO; Kim, YJ; Kwon, SY	1
Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR	1
Adami, S; Gatti, D; Rossini, M; Viapiana, O	1
Mészaros, Á; Veszelyné Kotán, E	1
Kõks, S; Laius, O; Maasalu, K; Märtson, A	1
Baek, HJ; Choe, JY; Kang, SW; Lee, SG; Lee, YJ; Park, SH; Park, W; Park, YB; Shin, K; Song, JS; Song, YW; Yoo, B; Yoo, DH; Yoo, WH	1
Papapoulos, SE; Schimmer, RC	2
Kastelan, D; Korsic, M; Vlak, T	1
Adachi, JD; Adami, S; Cooper, C; Cranney, A; Delmas, PD; Miller, PD; Papapoulos, S; Reginster, JY; Sambrook, PN; Silverman, S; Siris, E; Wells, GA; Yetisir, E	1
Hochberg, MC	1
Burge, RT; Lindsay, R; Marshall, DA; Tosteson, AN	1
Brown, JE; Coleman, RE; Dodwell, D; Ellis, SP; Gutcher, SA; Hannon, RA; Horsman, JM; Lester, JE; Purohit, OP; Thorpe, R	1
Body, JJ	1
Emkey, RD; Kohles, JD; Sambrook, PN; Sebba, AI	1
Emkey, RD	1
Barr, CE; Blumentals, WA; Harley, C; Harris, ST; Poston, SA; Reginster, JY; Silverman, SL	1
Adachi, JD; Cranney, A; Sambrook, P	1
Hommann, M; Kaemmerer, D; Lehmann, G; Settmacher, U; Wolf, G	1
Cole, R	1
Griffith, JF; Hung, VY; Kwok, AW; Lee, KK; Lee, VW; Leung, PC; Li, EK; Li, M; Qin, L; Tam, LS; Wong, KC; Zhu, TY	1
Jones, G; Winzenberg, T	1
Adler, G; Herdt, K; Klaus, J; Reinshagen, M; Schröter, C; von Boyen, GB; von Tirpitz, C	1
Abarca, J; Campbell, HE; Martin, KE; White, TJ; Yu, J	1
Amrein, K; Dimai, HP; Dobnig, H; Fahrleitner-Pammer, A; Kniepeiss, D; Kornprat, P; Pieber, T; Tscheliessnigg, KH; Wagner, D	1
Hommann, M; Kaemmerer, D; Lehmann, G; Schmidt, B; Settmacher, U; Wolf, G	1
Kutilek, S; Nemec, V; Plasilová, I	1
Black, DM; Eastell, R; Hietpas, J; Palermo, L; Schafer, AL; Sellmeyer, DE; Shoback, DM	1
Bala, Y; Boivin, G; Kohles, J; Recker, RR	1
Burckhardt, P; Burnand, J; Fatio, S; Lamy, O; Pache, I; Sandini, L	1
Bell, R; Bergstrom, B; Body, JJ; Diel, IJ; Lazarev, A; Lichinitzer, M; Pecherstorfer, M; Tripathy, D	1
Chesnut, CH; Christiansen, C; Delmas, PD; Ettinger, M; Hoiseth, A; Mahoney, P; Recker, R; Schimmer, RC; Skag, A; Stakkestad, JA	1
Chesnut, CH; Christiansen, C; Delmas, PD; Felsenberg, D; Gilbride, J; Hoiseth, A; Huss, H; Recker, R; Schimmer, RC; Skag, A; Stakkestad, JA	1
Hosking, DJ; Pande, I	1
Reginster, JY	1
Geusens, P; Reid, D	1
Polk, B	1
Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM	1
Dawson-Hughes, B; Gass, M	1
Díaz-Curiel, M; Moro Alvarez, MJ	1
Rizzoli, R	1
Blumentals, WA; Harris, ST; Miller, PD	1
Alva, D; Cesareo, R; Contini, S; De Rosa, B; Iozzino, M; Lauria, A; Mallardo, L; Napolitano, C; Orsini, A; Reda, G	1
Bergman, G; Gaugris, S; Jansen, JP; Sen, SS	1
Skoglund, B	1
Kastelan, D; Vlak, T	1
Klaus, J; König, HH; Konnopka, A; Kreck, S; Leidl, R; Matschinger, H; von Tirpitz, C	1
Bauss, F; Kim, SZ; Kurth, AA; Sedlmeyer, I; Shea, M	1
Boewer, C; Delmas, PD; Euller-Ziegler, L; Facon, T; Fiere, D; Fontana, A; Herrmann, Z; Hrubisko, M; Lichinitser, MR; Menssen, HD; Sakalová, A; Singer, CR; Thiel, E; Wetterwald, M	1

Reviews

19 review(s) available for ibandronic acid and Bone Fractures

Article	Year
Polypharmacy in Osteoporosis Treatment. Clinics in geriatric medicine, 2022, Volume: 38, Issue:4 Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Polypharmacy; Risedronic Acid; Teriparatide; Zoledronic Acid	2022
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis. PloS one, 2015, Volume: 10, Issue:5 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Hydroxycholecalciferols; Ibandronic Acid; Imidazoles; Lumbar Vertebrae; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid	2015
The use of bisphosphonates in women: when to use and when to stop. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:16 Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors; Time Factors; Zoledronic Acid	2015
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid	2016
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:2 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Randomized Controlled Trials as Topic; Treatment Outcome	2009
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. Current osteoporosis reports, 2008, Volume: 6, Issue:3 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid	2008
[Update on treatment of postmenopausal osteoporosis]. Revue medicale de Bruxelles, 2008, Volume: 29, Issue:4 Topics: Bone Resorption; Calcium; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Zoledronic Acid	2008
Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone, 2009, Volume: 44, Issue:3 Topics: Aged; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis	2009
Quarterly intravenous ibandronate for postmenopausal osteoporosis. Women's health (London, England), 2008, Volume: 4, Issue:3 Topics: Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis, Postmenopausal; Treatment Outcome	2008
Oral antiresorptive therapy. Current rheumatology reports, 2005, Volume: 7, Issue:1 Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide	2005
Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:13 Topics: Administration, Oral; Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic	2005
Newer drug treatments: their effects on fracture prevention. Best practice & research. Clinical rheumatology, 2005, Volume: 19, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Denosumab; Diphosphonates; Fractures, Bone; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Organometallic Compounds; Osteoporosis; Osteoprotegerin; Parathyroid Hormone; RANK Ligand; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thiophenes; Zoledronic Acid	2005
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. Maturitas, 2006, Apr-20, Volume: 54, Issue:1 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Bone; Gastrointestinal Diseases; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid	2006
Preventing osteoporosis-related fractures: an overview. The American journal of medicine, 2006, Volume: 119, Issue:4 Suppl 1 Topics: Absorptiometry, Photon; Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fractures, Bone; Humans; Ibandronic Acid; Motor Activity; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Teriparatide; United States; Vitamin D	2006
Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Annals of the rheumatic diseases, 2007, Volume: 66, Issue:7 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Treatment Outcome	2007
Pharmacological treatment of osteoporosis for people over 70. Aging clinical and experimental research, 2007, Volume: 19, Issue:3 Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risedronic Acid; Thiophenes; Vitamin D	2007
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Current medical research and opinion, 2008, Volume: 24, Issue:1 Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risk Factors; Time Factors	2008
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures. Minerva endocrinologica, 2007, Volume: 32, Issue:4 Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Vitamin D	2007
[Does ibandronate (Bonviva) have an impact on non-vertebral fractures?]. Reumatizam, 2007, Volume: 54, Issue:2 Topics: Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal	2007

Trials

19 trial(s) available for ibandronic acid and Bone Fractures

Article	Year
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcified tissue international, 2013, Volume: 93, Issue:2 Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Infusions, Intravenous; Japan; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Risedronic Acid; Spinal Fractures; Time Factors; Treatment Outcome	2013
Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:6 Topics: Administration, Oral; Aged; Alendronate; Bone Density; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Liver Cirrhosis, Biliary; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Treatment Outcome	2013
The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture. Thrombosis and haemostasis, 2013, Volume: 110, Issue:2 Topics: Adult; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Hemophilia A; Hemophilia B; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Prospective Studies; Risk Factors	2013
Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstetrics and gynecology, 2013, Volume: 121, Issue:6 Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; RANK Ligand	2013
Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2014, Volume: 29, Issue:2 Topics: Absorptiometry, Photon; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Biopsy; Bone Density; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Femur Neck; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis	2014
Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study. Calcified tissue international, 2014, Volume: 95, Issue:6 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid	2014
Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial. Clinical therapeutics, 2017, Volume: 39, Issue:2 Topics: Adult; Aged; Arthritis, Rheumatoid; Bone Density; Bone Diseases, Metabolic; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Peptides	2017
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Oct-01, Volume: 14, Issue:19 Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases; Breast Neoplasms; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Nitriles; Placebos; Triazoles	2008
Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA. Current medical research and opinion, 2010, Volume: 26, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fractures, Bone; Humans; Ibandronic Acid; Incidence; Infusions, Intravenous; Middle Aged	2010
Treatment of osteoporosis after liver transplantation with ibandronate. Transplant international : official journal of the European Society for Organ Transplantation, 2010, Volume: 23, Issue:7 Topics: Absorptiometry, Photon; Adult; Aged; Alkaline Phosphatase; Bone Density; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Liver Transplantation; Male; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone	2010
Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. Arthritis research & therapy, 2010, Volume: 12, Issue:5 Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Glucocorticoids; Humans; Hydroxycholecalciferols; Ibandronic Acid; Lupus Erythematosus, Systemic; Middle Aged; Osteoporosis; Prednisolone; Tomography Scanners, X-Ray Computed	2010
Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D. World journal of gastroenterology, 2011, Jan-21, Volume: 17, Issue:3 Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Calcium Citrate; Cholecalciferol; Crohn Disease; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Male; Middle Aged; Sodium Fluoride; Vitamin D; Young Adult	2011
Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:10 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Pilot Projects; Treatment Outcome	2012
Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization. Calcified tissue international, 2013, Volume: 92, Issue:1 Topics: Administration, Oral; Aged; Biopsy; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Regression Analysis; Reproducibility of Results; Treatment Outcome	2013
Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years. Journal of endocrinological investigation, 2003, Volume: 26, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone and Bones; Bone Density; Diphosphonates; Follow-Up Studies; Fractures, Bone; Humans; Ibandronic Acid; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Pilot Projects; Spine	2003
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. British journal of cancer, 2004, Mar-22, Volume: 90, Issue:6 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Morbidity; Placebos; Risk Factors	2004
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone, 2004, Volume: 34, Issue:5 Topics: Aged; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Osteoporosis; Placebos; Postmenopause	2004
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:8 Topics: Aged; Body Height; Bone and Bones; Bone Density; Diphosphonates; Double-Blind Method; Female; Femur; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Pelvic Bones; Prospective Studies; Risk Factors; Spinal Fractures; Treatment Outcome	2004
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, May-01, Volume: 20, Issue:9 Topics: Bone Resorption; Chi-Square Distribution; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Hypercalcemia; Ibandronic Acid; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Pain; Spinal Cord Compression; Survival Analysis; Treatment Outcome	2002

Other Studies

24 other study(ies) available for ibandronic acid and Bone Fractures

Article	Year
Real-world effectiveness of osteoporosis treatments in Germany. Archives of osteoporosis, 2022, 08-31, Volume: 17, Issue:1 Topics: Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Fractures, Bone; Germany; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Zoledronic Acid	2022
Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates. Archives of osteoporosis, 2017, Dec-21, Volume: 13, Issue:1 Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Bulgaria; Denosumab; Diphosphonates; Female; Femur Neck; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies	2017
Bad Breaks. Clinical chemistry, 2018, Volume: 64, Issue:1 Topics: Bone Density Conservation Agents; Calcium Citrate; Cholecalciferol; Female; Fractures, Bone; Humans; Hypocalcemia; Ibandronic Acid; Middle Aged; Osteoporosis; Pubic Bone; Sacrum; Vitamin D Deficiency	2018
Successful conservative treatment: multiple atypical fractures in osteoporotic patients after bisphosphate medication: a unique case report. Medicine, 2015, Volume: 94, Issue:5 Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femur; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal	2015
Use of drugs against osteoporosis in the Baltic countries during 2010-2014. Medicina (Kaunas, Lithuania), 2016, Volume: 52, Issue:5 Topics: Alendronate; Baltic States; Bone Density Conservation Agents; Calcium Channel Blockers; Denosumab; Diphosphonates; Drug Utilization; Ergocalciferols; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Risedronic Acid	2016
Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Postgraduate medical journal, 2008, Volume: 84, Issue:992 Topics: Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Treatment Outcome	2008
Ibandronate: is there an effect on nonvertebral fractures? Clinical rheumatology, 2008, Volume: 27, Issue:10 Topics: Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Meta-Analysis as Topic; Osteoporosis, Postmenopausal	2008
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. The American journal of managed care, 2008, Volume: 14, Issue:9 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Budgets; Cost-Benefit Analysis; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Health Care Costs; Humans; Ibandronic Acid; Markov Chains; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Risk Assessment; Risk Factors; United States	2008
Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone, 2009, Volume: 44, Issue:5 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Hip Fractures; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies	2009
Pricey osteoporosis remedy doesn't beat older drugs. Consumer reports, 2009, Volume: 74, Issue:8 Topics: Advertising; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium, Dietary; Diphosphonates; Drug Costs; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Vitamin D	2009
Postmenopausal osteoporosis: another approach to management. The Journal of family practice, 2010, Volume: 59, Issue:6 Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Medication Adherence; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risk Assessment; Secondary Prevention; Zoledronic Acid	2010
When do bisphosphonates make the most sense? The Journal of family practice, 2011, Volume: 60, Issue:1 Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; United States; Women's Health	2011
Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost. Journal of managed care pharmacy : JMCP, 2011, Volume: 17, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Comparative Effectiveness Research; Diphosphonates; Drug Costs; Etidronic Acid; Female; Follow-Up Studies; Fractures, Bone; Humans; Ibandronic Acid; Insurance Claim Review; Longitudinal Studies; Male; Managed Care Programs; Medication Adherence; Middle Aged; Osteoporosis; Regression Analysis; Retrospective Studies; Risedronic Acid; United States	2011
Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after LTX. Transplantation, 2012, Feb-15, Volume: 93, Issue:3 Topics: Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcitriol; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Bone; Humans; Ibandronic Acid; Liver Transplantation; Male; Middle Aged; Osteoporosis; Parathyroid Hormone; Risk	2012
Monthly ibandronate for the prevention of bone loss in patients after liver transplantation. Transplantation proceedings, 2012, Volume: 44, Issue:5 Topics: Absorptiometry, Photon; Administration, Oral; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chi-Square Distribution; Cholecalciferol; Creatinine; Dietary Supplements; Diphosphonates; Drug Administration Schedule; Femur Neck; Fractures, Bone; Germany; Humans; Ibandronic Acid; Liver Transplantation; Lumbar Vertebrae; Osteoporosis; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2012
Once-monthly oral ibandronate treatment in an adolescent with recurrent fractures and inadequately low bone mass. Journal of paediatrics and child health, 2012, Volume: 48, Issue:7 Topics: Adolescent; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Male; Recurrence	2012
Injectable drug dampens bone loss. Health news (Waltham, Mass.), 2003, Volume: 9, Issue:12 Topics: Bone Density; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal	2003
A new option for osteoporosis. The Johns Hopkins medical letter health after 50, 2005, Volume: 17, Issue:5 Topics: Diphosphonates; Drug Administration Schedule; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis	2005
[Ibandronate once a month]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:1 Topics: Bone Density Conservation Agents; Delayed-Action Preparations; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal	2006
Osteoporosis: non-hormonal treatment. Climacteric : the journal of the International Menopause Society, 2007, Volume: 10 Suppl 2 Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health	2007
Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands. Current medical research and opinion, 2008, Volume: 24, Issue:3 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Cost-Benefit Analysis; Diphosphonates; Drug Combinations; Drug Costs; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Models, Economic; Netherlands; Osteoporosis; Patient Compliance; Patient Simulation; Quality-Adjusted Life Years; United Kingdom	2008
Linköping University Medical Dissertation No. 1033. Following the mevalonate pathway to bone heal alley. Acta orthopaedica. Supplementum, 2007, Volume: 78, Issue:328 Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density Conservation Agents; Coated Materials, Biocompatible; Diphosphonates; Disease Models, Animal; Femoral Fractures; Fracture Healing; Fractures, Bone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Injections, Subcutaneous; Male; Mevalonic Acid; Mice; Mice, Inbred BALB C; Rats; Rats, Sprague-Dawley; Simvastatin	2007
Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model. PharmacoEconomics, 2008, Volume: 26, Issue:4 Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Calcium; Cholecalciferol; Cost-Benefit Analysis; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Bone; Germany; Humans; Ibandronic Acid; Inflammatory Bowel Diseases; Male; Markov Chains; Models, Economic; Osteoporosis; Quality-Adjusted Life Years; Sodium Fluoride	2008
Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. Bone, 2002, Volume: 30, Issue:1 Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Mammary Neoplasms, Experimental; Osteolysis; Rats; Rats, Sprague-Dawley; Sarcoma, Experimental	2002